Cargando…
ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study
INTRODUCTION: In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing‐based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician‐prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient‐reported chemotherapy t...
Autores principales: | Lee, Lennard Y. W., Starkey, Thomas, Sivakumar, Shivan, Fotheringham, Susan, Mozolowski, Guy, Shearwood, Vanessa, Palles, Claire, Camilleri, Philip, Church, David, Kerr, Rachel, Kerr, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797583/ https://www.ncbi.nlm.nih.gov/pubmed/31486228 http://dx.doi.org/10.1002/cam4.2529 |
Ejemplares similares
-
An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities
por: Palles, Claire, et al.
Publicado: (2021) -
Challenges and solutions in patient treatment strategies for stage II colon cancer
por: Fotheringham, Susan, et al.
Publicado: (2019) -
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma
por: Guo, Longbin, et al.
Publicado: (2020) -
The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States—part 3: Hispanic-American patients
por: McClelland, Shearwood, et al.
Publicado: (2017) -
Implementing Microsoft Dynamics NAV 2009
por: Roys, David, et al.
Publicado: (2009)